CA2862483A1 - Sandalwood oil and its uses related to clostridium infections - Google Patents

Sandalwood oil and its uses related to clostridium infections Download PDF

Info

Publication number
CA2862483A1
CA2862483A1 CA2862483A CA2862483A CA2862483A1 CA 2862483 A1 CA2862483 A1 CA 2862483A1 CA 2862483 A CA2862483 A CA 2862483A CA 2862483 A CA2862483 A CA 2862483A CA 2862483 A1 CA2862483 A1 CA 2862483A1
Authority
CA
Canada
Prior art keywords
infection
subject
clostridium
sandalwood oil
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2862483A
Other languages
English (en)
French (fr)
Inventor
Ian Clements
Paul Castella
Corey Levenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANTALIS PHARMACEUTICALS Inc
Original Assignee
SANTALIS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANTALIS PHARMACEUTICALS Inc filed Critical SANTALIS PHARMACEUTICALS Inc
Publication of CA2862483A1 publication Critical patent/CA2862483A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2862483A 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections Abandoned CA2862483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589601P 2012-01-23 2012-01-23
US61/589,601 2012-01-23
PCT/US2013/022743 WO2013112582A1 (en) 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections

Publications (1)

Publication Number Publication Date
CA2862483A1 true CA2862483A1 (en) 2013-08-01

Family

ID=48873861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2862483A Abandoned CA2862483A1 (en) 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections

Country Status (6)

Country Link
US (2) US9579354B2 (cg-RX-API-DMAC7.html)
EP (1) EP2806882B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134739B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013212264B2 (cg-RX-API-DMAC7.html)
CA (1) CA2862483A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013112582A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154342A1 (en) * 2011-07-28 2014-06-05 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to skin disorders
WO2014160279A1 (en) 2013-03-13 2014-10-02 Viroxis Corporation Stabilized cream formulations comprising sandalwood oil
JP2018529752A (ja) 2015-10-07 2018-10-11 サンタリス ファーマシューティカルズ インコーポレイテッド サンダルウッド油及び口腔粘膜炎に関連するその用途
WO2018165108A1 (en) 2017-03-08 2018-09-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
KR102647803B1 (ko) 2017-03-08 2024-03-15 호프 메디칼 엔터프라이즈스, 인크, 디비에이, 호프파마수으티칼즈 아질산나트륨의 투석중 용도
CA3109900A1 (en) * 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
CN111544353A (zh) * 2020-05-21 2020-08-18 天津芸熙生物技术有限公司 一种抑菌口腔喷雾剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
JP2006124296A (ja) * 2004-10-27 2006-05-18 Tomihiko Higuchi ヘリコバクター・ピロリ菌感染症治療のための医薬組成物
US7858126B2 (en) * 2006-08-31 2010-12-28 Trinity Laboratories Inc. Derivatives of sandalwood oil and santalols for treating cold sores and herpes
WO2009014781A2 (en) * 2007-05-02 2009-01-29 Nucryst Pharmaceuticals Corp. Metal-containing materials for treatment of bacterial conditions
KR101842289B1 (ko) * 2010-03-01 2018-03-26 산탈리스 파마슈티컬스, 인크. 백단유 및 이의 용도
AU2011239470B2 (en) 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
US20130224164A1 (en) * 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use

Also Published As

Publication number Publication date
US20150238551A1 (en) 2015-08-27
EP2806882A1 (en) 2014-12-03
JP2015505540A (ja) 2015-02-23
EP2806882A4 (en) 2015-08-05
AU2013212264B2 (en) 2017-05-18
US10322154B2 (en) 2019-06-18
US20170128509A1 (en) 2017-05-11
EP2806882B1 (en) 2018-11-14
US9579354B2 (en) 2017-02-28
JP6134739B2 (ja) 2017-05-24
AU2013212264A1 (en) 2014-08-07
WO2013112582A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US10322154B2 (en) Sandalwood oil and its uses related to clostridium infections
Tactacan et al. A Bacillus subtilis (QST 713) spore-based probiotic for necrotic enteritis control in broiler chickens
US20130136695A1 (en) Methods and compositions including spore-forming bacteria for increasing the health of animals
EP3444330B1 (en) Strain of genus agathobaculum having effects of preventing or treating degenerative brain diseases, and use thereof
AU2019229354B2 (en) Volatile organic compound formulations having antimicrobial activity
Heres et al. Effect of fermented feed on the susceptibility for Campylobacter jejuni colonisation in broiler chickens with and without concurrent inoculation of Salmonella enteritidis
US20180028490A1 (en) Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-Human Animals
KR20210004221A (ko) 알파-망고스틴, 감마-망고스틴 또는 셀라스트롤을 포함하는 항균활성을 가진 조성물
KR20210053637A (ko) 케피어 유래 프로바이오틱 효모 클루이베로미세스 막시아누스 a5 및 이의 용도
Moore et al. The effect of an experimental chlorate product on Salmonella recovery of turkeys when administered prior to feed and water withdrawal
KR20090078065A (ko) 항균효과가 강화된 사료첨가용 유산균제제 와 그 제조방법
CA3117821A1 (en) Volatile organic compound formulations having antimicrobial activity
US12097173B2 (en) Volatile organic compound formulations having antimicrobial activity
KR102208837B1 (ko) 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물
EA043409B1 (ru) Ветеринарное пробиотическое средство
HK40025284A (en) Volatile organic compound formulations having antimicrobial activity
CN105998312A (zh) 治疗鸡禽沙门氏菌病的中药组合物及鸡饲料
RU2802308C2 (ru) Композиции летучих органических веществ, обладающие антимикробной активностью
Kantas et al. A feed additive containing Bacillus toyonensis in weaning piglets
NZ715859B2 (en) Volatile organic compound formulations having antimicrobial activity
JP2010126472A (ja) クロストリジウム症の予防及び/又は治療用飼料

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171123

FZDE Discontinued

Effective date: 20200831